Developer docs
API playgroundTry for free, no card

Search company profiles

Beacon Therapeutics

Full company profile

uuid0000bov

Namestring
Beacon Therapeutics
Legal namestring
Beacon Therapeutics Holdings Limited
Websiteurl
beacontx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Beacon Therapeutics Holdings Limited is a clinical-stage biotechnology company founded in 2023 and dual-headquartered in London, UK and Cambridge, Massachusetts. It develops adeno-associated virus (AAV)-based gene therapies intended to preserve and restore vision in patients with rare and prevalent blinding ocular diseases. Its pipeline is built on a single integrated AAV platform comprising proprietary engineered capsids and codon-optimized gene cassettes, with manufacturing capability scaled from research to clinical-grade GMP production through a long-term partnership with Ascend in Alachua, Florida.

The lead asset is laru-zova (laruparetigene zovaparvovec, formerly AGTC-501), a subretinal AAV gene therapy delivering a functional copy of the RPGR gene to express the full-length RPGR protein for the treatment of X-linked retinitis pigmentosa (XLRP). It is currently in a registrational Phase 2/3 VISTA trial (85 male participants enrolled across North America, the UK and Australia; topline data expected H2 2026), supported by Phase 2 DAWN and SKYLINE data and Phase 1/2 HORIZON long-term safety data, and holds FDA RMAT, FDA Fast Track, FDA Orphan Drug, EMA PRIME, EMA Orphan Drug and UK MHRA ILAP designations. Beyond XLRP, the pipeline includes BTX-001 (intravitreal AAV gene therapy delivering a C5 inhibitor for geographic atrophy secondary to dry AMD) and a preclinical CDHR1 program for inherited cone-rod dystrophy licensed from Professor Robert MacLaren's laboratory at the University of Oxford.

Beacon is privately held, pre-revenue and capital-funded: it has raised approximately £96M in Series A (Jun 2023), $170M in Series B (Jul 2024) and over $75M in Series C (Jan 2026), with Syncona Limited as the largest institutional shareholder. The senior leadership team — CEO Lance Baldo (former Lucentis franchise head at Genentech), CMO Daniel Chung (former Spark Therapeutics, instrumental in Luxturna development) and CSO Abraham Scaria (25 years of gene therapy R&D) — reflects a deliberate pivot from discovery-led operations toward commercial readiness for a future laru-zova launch, which would target specialty ophthalmology and inherited retinal disease centers globally.

Short descriptiontext

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies for rare and prevalent blinding ocular diseases, with lead asset laru-zova in a registrational Phase 2/3 XLRP trial (H2 2026 readout) and preclinical programs in geographic atrophy and cone-rod dystrophy; the company is pre-revenue and has raised over $365M since its 2023 founding.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic gene therapy, AAV gene therapy, retinal disease treatments, inherited retinal diseases, ocular biotechnology
Industry4 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Ophthalmic Gene Therapy
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model1 record
1Future commercialization of laru-zova
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company. Plans future commercialization of lead asset laru-zova for X-linked retinitis pigmentosa (XLRP), with potential label expansion into other retinal diseases. Currently accelerating commercial preparations but no product revenue generated to date.

beacontx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies to preserve and restore vision in patients with rare and prevalent ocular diseases. Its lead investigational product, laru-zova (laruparetigene zovaparvovec/AGTC-501), is being evaluated for X-linked retinitis pigmentosa (XLRP) in a registrational Phase 2/3 VISTA trial. Additional pipeline candidates include BTX-001 for geographic atrophy secondary to dry AMD and a CDHR1 program for cone-rod dystrophy, all built on the company's proprietary AAV capsid and codon-optimized gene cassette platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Beacon Therapeutics is a clinical-stage biotechnology company built around a single integrated AAV gene therapy platform that powers its pipeline of ocular disease treatments. The core proprietary AAV gene therapy platform (incorporating engineered capsids and optimized genome cassettes) underpins the lead asset laru-zova (laruparetigene zovaparvovec / AGTC-501), a late-stage gene therapy for X-linked retinitis pigmentosa (XLRP) currently in a registrational Phase 2/3 VISTA trial with topline data expected in H2 2026, alongside ongoing Phase 2 trials (DAWN, SKYLINE) and the Phase 1/2 LANDSCAPE bilateral dosing study. The same platform feeds two preclinical programs: BTX-001, an intravitreal AAV gene therapy delivering a C5 inhibitor for geographic atrophy secondary to dry AMD, and the CDHR1 program targeting inherited cone-rod dystrophy, licensed from Professor Robert MacLaren's laboratory at the University of Oxford. Together, these assets form a portfolio spanning rare inherited and prevalent ocular diseases, supported by GMP manufacturing partnerships for clinical and commercial supply.

Product and service2 records
1laru-zova (laruparetigene zovaparvovec / AGTC-501)
CategoryLead clinical-stage gene therapy candidate
Description

Investigational AAV vector-based gene therapy delivering a functional copy of the RPGRORF15 gene to express full-length RPGR protein in both rods and cones, administered via subretinal injection to patients with X-linked retinitis pigmentosa. Currently in a registrational Phase 2/3 VISTA trial (85 participants enrolled) with topline data expected H2 2026.

2BTX-001
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-08
Description

J.P. Morgan acted as sole placement agent to Beacon Therapeutics for the $170M Series B financing transaction in July 2024. Provides investment banking advisory services for capital raises.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-01-07
Description

Described as 'second pharma venture partner' providing new financing. Listed alongside Boehringer Ingelheim Ventures as pharma venture partner. Specific strategic scope not detailed in source.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-11
Description

Non-exclusive agreement for Beacon to evaluate Abeona's patented AAV204 capsid for development and commercialization of gene therapies for select ophthalmology indications. Beacon has 12-month evaluation period with option to take worldwide non-exclusive license for up to 5 gene/disease targets plus right to use for up to 4 additional targets. Abeona receives upfront payment on option exercise plus milestones and tiered royalties on net sales.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-06-12
Description

Network of clinical trial sites across North America, United Kingdom, and Australia conducting the registrational Phase 2/3 VISTA trial of laru-zova in 85 male XLRP patients. Sites include academic medical centers and specialty ophthalmology clinics.

5Ascend (GMP Manufacturing, Alachua, Florida)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-09
Description

Ascend acquired GMP manufacturing capacity in Alachua, Florida and entered long-term partnership with Beacon for clinical and commercial AAV production. Secures GMP drug supply for Beacon's clinical trials and future commercial supply chain.

beacontx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-12
Description

CDHR1 program for inherited Cone Rod Dystrophy licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the University of Oxford. Foundation scientific asset for Beacon's preclinical CRD program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including XLRP (RPGR) and other ocular indications. Directly competes with Beacon in XLRP using a different AAV capsid delivery approach.

TypeDirect peer
Description

Clinical-stage gene therapy company with lead programs in wet AMD and other ocular diseases using AAV-based intravitreal delivery. Directly comparable in ocular gene therapy modality and ophthalmic target indications.

TypeDirect peer
Description

Clinical-stage gene therapy company developing customized AAV vectors for ophthalmology (including XLRP) and other rare diseases. Directly comparable as an AAV platform gene therapy peer targeting inherited retinal diseases.

TypeDirect peer
Description

Clinical-stage gene therapy company with proprietary NAV Technology AAV platform and multiple ophthalmology programs including retinal and rare ocular disease indications. Comparable as a competing AAV platform peer pursuing ocular gene therapy.

TypeDirect peer
Description

Developer of Luxturna, the first FDA-approved ocular gene therapy for RPE65-mediated inherited retinal dystrophy. Now part of Roche, Spark set the commercial and regulatory precedent for ophthalmic gene therapy that Beacon is following.

TypeDirect peer
Description

Acquired by Astellas in 2023, IVERIC Bio developed Izervay (avacincaptad pegol) for geographic atrophy and previously advanced gene therapy programs for inherited retinal diseases. Directly comparable as a retinal gene therapy and GA peer.

TypeDirect peer
Description

Acquired by Novartis in 2022, Gyroscope developed gene therapy for geographic atrophy secondary to dry AMD. Directly comparable as a competing ocular gene therapy player in the GA indication that Beacon is pursuing with BTX-001.

TypeOthers
Description

Predecessor company acquired by Syncona in 2022 that originated the XLRP gene therapy program now being developed as laru-zova by Beacon Therapeutics. Establishes the scientific foundation and prior clinical work underlying Beacon's lead asset.

TypeEmerging player
Description

Commercial-stage gene therapy company with Vyjuvek, the first FDA-approved topical gene therapy. Comparable as a rare disease gene therapy peer with demonstrated capability to advance AAV-based therapies through FDA approval and commercial launch.

TypeBroad incumbent
Description

Roche/Genentech commercializes Lucentis (ranibizumab) and Susvimo for wet AMD and other retinal diseases. Comparable as the established ophthalmic biopharmaceutical incumbent whose Lucentis launch was led by Beacon CEO Lance Baldo and which set pricing/precedent dynamics in the retinal disease space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beacon Therapeutics

Ophthalmic Gene Therapybeacontx.com

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies for rare and prevalent blinding ocular diseases, with lead asset laru-zova in a registrational Phase 2/3 XLRP trial (H2 2026 readout) and preclinical programs in geographic atrophy and cone-rod dystrophy; the company is pre-revenue and has raised over $365M since its 2023 founding.

What Beacon Therapeutics does

Beacon Therapeutics Holdings Limited is a clinical-stage biotechnology company founded in 2023 and dual-headquartered in London, UK and Cambridge, Massachusetts. It develops adeno-associated virus (AAV)-based gene therapies intended to preserve and restore vision in patients with rare and prevalent blinding ocular diseases. Its pipeline is built on a single integrated AAV platform comprising proprietary engineered capsids and codon-optimized gene cassettes, with manufacturing capability scaled from research to clinical-grade GMP production through a long-term partnership with Ascend in Alachua, Florida.

The lead asset is laru-zova (laruparetigene zovaparvovec, formerly AGTC-501), a subretinal AAV gene therapy delivering a functional copy of the RPGR gene to express the full-length RPGR protein for the treatment of X-linked retinitis pigmentosa (XLRP). It is currently in a registrational Phase 2/3 VISTA trial (85 male participants enrolled across North America, the UK and Australia; topline data expected H2 2026), supported by Phase 2 DAWN and SKYLINE data and Phase 1/2 HORIZON long-term safety data, and holds FDA RMAT, FDA Fast Track, FDA Orphan Drug, EMA PRIME, EMA Orphan Drug and UK MHRA ILAP designations. Beyond XLRP, the pipeline includes BTX-001 (intravitreal AAV gene therapy delivering a C5 inhibitor for geographic atrophy secondary to dry AMD) and a preclinical CDHR1 program for inherited cone-rod dystrophy licensed from Professor Robert MacLaren's laboratory at the University of Oxford.

Beacon is privately held, pre-revenue and capital-funded: it has raised approximately £96M in Series A (Jun 2023), $170M in Series B (Jul 2024) and over $75M in Series C (Jan 2026), with Syncona Limited as the largest institutional shareholder. The senior leadership team — CEO Lance Baldo (former Lucentis franchise head at Genentech), CMO Daniel Chung (former Spark Therapeutics, instrumental in Luxturna development) and CSO Abraham Scaria (25 years of gene therapy R&D) — reflects a deliberate pivot from discovery-led operations toward commercial readiness for a future laru-zova launch, which would target specialty ophthalmology and inherited retinal disease centers globally.

Beacon Therapeutics firmographics

Firmographics
Name
Beacon Therapeutics
Legal name
Beacon Therapeutics Holdings Limited
Website
https://beacontx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies for rare and prevalent blinding ocular diseases, with lead asset laru-zova in a registrational Phase 2/3 XLRP trial (H2 2026 readout) and preclinical programs in geographic atrophy and cone-rod dystrophy; the company is pre-revenue and has raised over $365M since its 2023 founding.
Ownership category
akta.pro rank

Beacon Therapeutics industry classification

Industry
Product category
Ophthalmic Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Ophthalmic gene therapy
  • AAV gene therapy
  • Retinal disease treatments
  • Inherited retinal diseases
  • Ocular biotechnology

Where Beacon Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Beacon Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Future commercialization of laru-zova: Pre-revenue clinical-stage biotechnology company. Plans future commercialization of lead asset laru-zova for X-linked retinitis pigmentosa (XLRP), with potential label expansion into other retinal diseases. Currently accelerating commercial preparations but no product revenue generated to date.

Go-to-market motion4 records

Distribution channels2 records

Marketing channels6 records

Beacon Therapeutics product offering

Product offering

Core offering

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies to preserve and restore vision in patients with rare and prevalent ocular diseases. Its lead investigational product, laru-zova (laruparetigene zovaparvovec/AGTC-501), is being evaluated for X-linked retinitis pigmentosa (XLRP) in a registrational Phase 2/3 VISTA trial. Additional pipeline candidates include BTX-001 for geographic atrophy secondary to dry AMD and a CDHR1 program for cone-rod dystrophy, all built on the company's proprietary AAV capsid and codon-optimized gene cassette platform.

Product overview

Beacon Therapeutics is a clinical-stage biotechnology company built around a single integrated AAV gene therapy platform that powers its pipeline of ocular disease treatments. The core proprietary AAV gene therapy platform (incorporating engineered capsids and optimized genome cassettes) underpins the lead asset laru-zova (laruparetigene zovaparvovec / AGTC-501), a late-stage gene therapy for X-linked retinitis pigmentosa (XLRP) currently in a registrational Phase 2/3 VISTA trial with topline data expected in H2 2026, alongside ongoing Phase 2 trials (DAWN, SKYLINE) and the Phase 1/2 LANDSCAPE bilateral dosing study. The same platform feeds two preclinical programs: BTX-001, an intravitreal AAV gene therapy delivering a C5 inhibitor for geographic atrophy secondary to dry AMD, and the CDHR1 program targeting inherited cone-rod dystrophy, licensed from Professor Robert MacLaren's laboratory at the University of Oxford. Together, these assets form a portfolio spanning rare inherited and prevalent ocular diseases, supported by GMP manufacturing partnerships for clinical and commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • laru-zova (laruparetigene zovaparvovec / AGTC-501) Investigational AAV vector-based gene therapy delivering a functional copy of the RPGRORF15 gene to express full-length RPGR protein in both rods and cones, administered via subretinal injection to patients with X-linked retinitis pigmentosa. Currently in a registrational Phase 2/3 VISTA trial (85 participants enrolled) with topline data expected H2 2026.
  • BTX-001

Companies that use Beacon Therapeutics

Customer profile

Segments4 records

Ideal customer profiles1 record

Beacon Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Beacon Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • J.P. Morgan (placement agent)minorImplementation/ SI/ Consulting Partner · 8 January 2026J.P. Morgan acted as sole placement agent to Beacon Therapeutics for the $170M Series B financing transaction in July 2024. Provides investment banking advisory services for capital raises.
  • RecordatiminorGTM or Marketing Partner · 7 January 2026Described as 'second pharma venture partner' providing new financing. Listed alongside Boehringer Ingelheim Ventures as pharma venture partner. Specific strategic scope not detailed in source.
  • Abeona TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 11 July 2024Non-exclusive agreement for Beacon to evaluate Abeona's patented AAV204 capsid for development and commercialization of gene therapies for select ophthalmology indications. Beacon has 12-month evaluation period with option to take worldwide non-exclusive license for up to 5 gene/disease targets plus right to use for up to 4 additional targets. Abeona receives upfront payment on option exercise plus milestones and tiered royalties on net sales.
  • Clinical trial sites (North America, UK, Australia)coreImplementation/ SI/ Consulting Partner · 12 June 2024Network of clinical trial sites across North America, United Kingdom, and Australia conducting the registrational Phase 2/3 VISTA trial of laru-zova in 85 male XLRP patients. Sites include academic medical centers and specialty ophthalmology clinics.
  • Ascend (GMP Manufacturing, Alachua, Florida)coreStrategic or Co-development Partner · 9 April 2024Ascend acquired GMP manufacturing capacity in Alachua, Florida and entered long-term partnership with Beacon for clinical and commercial AAV production. Secures GMP drug supply for Beacon's clinical trials and future commercial supply chain.
  • University of Oxford (Professor Robert MacLaren)coreStrategic or Co-development Partner · 12 June 2023CDHR1 program for inherited Cone Rod Dystrophy licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the University of Oxford. Foundation scientific asset for Beacon's preclinical CRD program.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

Beacon Therapeutics competitors and assessment

Company assessment

Direct peers

  • MeiraGTx Holdings: Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including XLRP (RPGR) and other ocular indications. Directly competes with Beacon in XLRP using a different AAV capsid delivery approach.
  • Adverum Biotechnologies: Clinical-stage gene therapy company with lead programs in wet AMD and other ocular diseases using AAV-based intravitreal delivery. Directly comparable in ocular gene therapy modality and ophthalmic target indications.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company developing customized AAV vectors for ophthalmology (including XLRP) and other rare diseases. Directly comparable as an AAV platform gene therapy peer targeting inherited retinal diseases.
  • REGENXBIO: Clinical-stage gene therapy company with proprietary NAV Technology AAV platform and multiple ophthalmology programs including retinal and rare ocular disease indications. Comparable as a competing AAV platform peer pursuing ocular gene therapy.
  • Spark Therapeutics (Roche): Developer of Luxturna, the first FDA-approved ocular gene therapy for RPE65-mediated inherited retinal dystrophy. Now part of Roche, Spark set the commercial and regulatory precedent for ophthalmic gene therapy that Beacon is following.
  • IVERIC Bio (Astellas): Acquired by Astellas in 2023, IVERIC Bio developed Izervay (avacincaptad pegol) for geographic atrophy and previously advanced gene therapy programs for inherited retinal diseases. Directly comparable as a retinal gene therapy and GA peer.
  • Gyroscope Therapeutics (Novartis): Acquired by Novartis in 2022, Gyroscope developed gene therapy for geographic atrophy secondary to dry AMD. Directly comparable as a competing ocular gene therapy player in the GA indication that Beacon is pursuing with BTX-001.

Others

Emerging players

  • Krystal Biotech: Commercial-stage gene therapy company with Vyjuvek, the first FDA-approved topical gene therapy. Comparable as a rare disease gene therapy peer with demonstrated capability to advance AAV-based therapies through FDA approval and commercial launch.

Broad incumbents

  • Genentech/Roche (Lucentis): Roche/Genentech commercializes Lucentis (ranibizumab) and Susvimo for wet AMD and other retinal diseases. Comparable as the established ophthalmic biopharmaceutical incumbent whose Lucentis launch was led by Beacon CEO Lance Baldo and which set pricing/precedent dynamics in the retinal disease space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Beacon Therapeutics social profiles

Digital presence

Beacon Therapeutics compliance and trust

Trust signal

Compliance7 records

Beacon Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beacon Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Beacon Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Beacon Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beacon Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beacon Therapeutics

What does Beacon Therapeutics do?

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies to preserve and restore vision in patients with rare and prevalent ocular diseases. Its lead investigational product, laru-zova (laruparetigene zovaparvovec/AGTC-501), is being evaluated for X-linked retinitis pigmentosa (XLRP) in a registrational Phase 2/3 VISTA trial. Additional pipeline candidates include BTX-001 for geographic atrophy secondary to dry AMD and a CDHR1 program for cone-rod dystrophy, all built on the company's proprietary AAV capsid and codon-optimized gene cassette platform.

Is Beacon Therapeutics a public or private company?

Beacon Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Beacon Therapeutics founded?

Beacon Therapeutics was founded in 2023. It employs 51 to 100 people.

Where is Beacon Therapeutics based?

Beacon Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does Beacon Therapeutics make money?

One revenue line is on record: future commercialization of laru-zova.

Who are Beacon Therapeutics's main competitors?

Direct peers on record are MeiraGTx Holdings, Adverum Biotechnologies, 4D Molecular Therapeutics, REGENXBIO, Spark Therapeutics (Roche), IVERIC Bio (Astellas) and Gyroscope Therapeutics (Novartis). Applied Genetic Technologies Corp (AGTC, acquired by Syncona) is listed as an others. Krystal Biotech is listed as an emerging player. Genentech/Roche (Lucentis) is listed as a broad incumbent.

Does Beacon Therapeutics have an API?

No public API is recorded for Beacon Therapeutics.

What industry is Beacon Therapeutics in?

Beacon Therapeutics's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Sharecast.comSyncona NAV rises as Beacon breakthrough boosts valuationSyncona reported a 3% net asset value per share increase in the first half, driven by positive Beacon Therapeutics trial results. NAV rose to 175.7p, and the company reiterated plans to return at least £250m to shareholders. Beacon's gene therapy met its primary endpoint, supporting a regulatory filing.Business & FinancialBeacon Therapeutics To Participate In Jefferies 2026 Global Healthcare Conference In LondonBeacon Therapeutics will participate in Jefferies' 2026 Global Healthcare Conference in London. The company reported positive topline data in the pivotal VISTA trial of its lead asset laru-zova for X-linked retinitis pigmentosa. Its pipeline also targets geographic atrophy secondary to dry AMD.GlobeNewswireBeacon Therapeutics Presents Data from Pivotal VISTA Trial of Laru-zova at AAO 2026Beacon Therapeutics presented data from its pivotal VISTA trial of laru-zova for X-linked retinitis pigmentosa at the AAO 2026 meeting. The trial met its FDA-endorsed primary endpoint, with 31.0% of high-dose and 24.1% of low-dose participants achieving ≥15-letter LLVA improvement at Month 12 versus no responders in control. Beacon plans a rolling BLA submission later this year.PR NewswireRetinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsightThe retinitis pigmentosa treatment market is expected to grow through 2036, with the US leading in 2025. Approximately 274,000 prevalent cases were diagnosed in the 7MM in 2025, and a growing pipeline of gene therapies is anticipated to broaden treatment options.Longevity.TechnologyBeacon Therapeutics’ gene therapy shows positive results for rare vision lossBeacon Therapeutics reported positive topline results from its VISTA trial of laruparetigene zovaparvovec in male patients with X-linked retinitis pigmentosa. At month 12, 31% of high-dose and 24% of low-dose participants achieved ≥15-letter low luminance visual acuity gain versus none in control. The company plans pre-submission engagement and a rolling BLA submission later this year.pharmaphorumBeacon's XLRP gene therapy set for filing after phase 3 winBeacon Therapeutics plans to file for approval of its gene therapy for X-linked retinitis pigmentosa after a phase 2/3 trial showed a 31% responder rate at 12 months. The therapy, laru-zova, would be the first treatment for XLRP and the first ocular gene therapy since Luxturna in 2017.BioPharma DiveBeacon eye gene therapy hits mark in late-stage studyBeacon Therapeutics' gene therapy laru-zova helped 24% of low-dose and 31% of high-dose patients with X-linked retinitis pigmentosa achieve at least 15 more letters on a low-light vision test, versus none in the control group. The company plans to submit a rolling approval application by year-end.Investing.comSyncona jumps 6% after Beacon gene therapy trial success By Investing.comBeacon Therapeutics said its VISTA trial met its primary endpoint, with 31% of high-dose and 24.1% of low-dose patients improving by at least 15 letters in visual acuity versus none in control. The company plans to begin regulator discussions and a rolling Biologics License Application later this year.Investing.comSyncona jumps 6% after Beacon gene therapy trial success By Investing.comBeacon Therapeutics reported that its late-stage VISTA trial of laruparetigene zovaparvovec met its primary endpoint, with 31% of high-dose and 24.1% of low-dose patients improving by at least 15 letters in visual acuity versus none in control. The company plans to begin regulator discussions and a rolling Biologics License Application later this year.Sharecast.comShares in Sycona jump on positive drug trial resultsSyncona shares jumped nearly 8% after its portfolio company Beacon Therapeutics reported positive topline results for laru-zova, a gene therapy for XLRP. The phase II/III trial met its primary endpoint of statistically significant low luminesce visual acuity. Beacon plans to engage regulators, with a rolling biologics licence application expected later this year.